乙型肝炎病毒阿德福韦酯耐药相关变异的研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.029

摘要/Abstract

摘要： 目前口服核苷酸类似物阿德福韦酯（adefovir dipivoxil,ADV）仍是我国临床治疗慢性乙型肝炎（chronic hepatitis B,CHB）的主要抗病毒药物之一。但是,长期服用ADV可能导致乙型肝炎病毒（hepatitis B virus,HBV）产生耐药变异。经典的ADV耐药变异形式为rtA181V和rtN236T,新鉴定的ADV原发耐药变异为rtA181S、rtE218G和rtN236V。此外,rtA181T、rtV214A、rtQ215H/P/S、rtL217R/P、rtI233V和rtN238T/D/H等位点变异与HBV对ADV耐药仍存在争议,尚需进一步明确。

关键词: 乙型肝炎病毒, 阿德福韦酯, 耐药, 基因变异, 抗病毒治疗

Abstract: Adefovir dipivoxil（ADV）,an oral nucleotide analogue,remains as one of the major antiviral agents in the treatment of chronic hepatitis B（CHB） in China. However,long-term therapy with ADV may lead to hepatitis B virus（HBV） drug-resistant mutations. The signature mutations associated with ADV resistance are rtA181V and rtN236T. The newly-identified ADV primary resistant mutations are rtA181S,rtE218G and rtN236V. In addition,some other mutations including rtA181T,rtV214A, rtQ215H/P/S,rtL217R/P,rtI233V,and rtN238T/D/H remain contradictory,and these mutations need to be further identified.

Key words: hepatitis B virus, Adefovir dipivoxil, Drug resistance, Gene mutation, Antiviral therapy

叶晓玲, 刘妍, 徐东平. 乙型肝炎病毒阿德福韦酯耐药相关变异的研究进展^*[J]. 实用肝脏病杂志, 2015, 18(3): 312-316.

YE Xiaoling, LIU Yan, XU Dongping.. Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 312-316.

参考文献

[1] Masaru E,Hiroyasu M,Akihiro T,et al. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B.World J Gastroenterol,2014,20（34）:12031-12038.
[2] 徐东平, 刘妍. 结合基因型耐药突变检测与表型耐药分析探索乙肝病毒耐药的新认识. 解放军医学杂志,2012,37（6）:535-538.
[3] Segovia MC,Chacra W,Gordon SC. Adefovir dipivoxil in chronic hepatitis B:history and current uses. Expert Opin Pharmacother,2012,13（2）:245-254.
[4] 成军. 现代肝炎病毒分子生物学. 北京:北京科学出版社, 2009:944-957.
[5] Li W, Zhao J,Zou Z,et al. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection. Plos one, 2014, 9（2）:1-9.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 中华肝脏病杂志,2011,19（1）:13-24.
[7] Angus P,Vaughan R,Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology,2003,125（2）:292-297.
[8] Borroto-Esoda K,Miller MD,Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol,2007,47（4）:492-498.
[9] Zhou X,Kuang X,Wang Y,et al. Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance. J Med Virol,2012,84（7）:1030-1036.
[10] Villet S, Pichoud C,Zoulim F,et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol,2008,48（5）:747-755.
[11] Liu Y,Li X,Xin S,et al. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. J Viral Hepat,2014,8（14）:1-7.
[12] Lok AS,Zoulim F,Locarnini S,et al.Antiviral drug-resistant HBV:standardizetion of nomenclature and assays and recommendations for management. Hepatology,2007,46（1）:254-265.
[13] Liu L,Wang J,Du C,et al. rtE218G,a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B. J Viral Hepat,2010,17（1）:66-72.
[14] Liu Y,Liu W,Xu D,et al. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V,of HBV from a large cohort of HBV-infected patients. Antivir Ther,2014,4（8）:1-8.
[15] Song B,Cui X,Shin J,et al. Response to adefovir depends on mutation patterns in precore region,basal core promoter and reverse transcriptase,and on-treatment responses in lamivudine-resistant chronic hepatitis B patients. Intervirology, 2010,53（4）:203-210.
[16] Chen C,Lee C,Tung W,et al. Evolution of full length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol,2010,52（4）:478-485.
[17] Gish R, Jia JD,Zoulim F,et al. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis, 2012,12（4）:341-353.
[18] European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185.
[19] Li X,Liu Y,Liu L,et al. Analysis of clinical profile and implications of hepatitis B virus rtA181T mutation. Hepatol Int, 2014,8:S101.2014 APASL.
[20] Ahn S,Park Y,Kim K,et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol,2014,88（12）:6805-6818.
[21] Yeh CT,Chen T,Hsu CW,et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer,2011,11:398.
[22] 胡爱荣, 蒋素文, 梁晓岳, 等. 浙江省东部地区慢性乙型肝炎病毒感染者阿德福韦酯相关位点病毒变异的临床特征分析, 中华医学杂志,2012,92（27）:1878-1881.
[23] Westland CE,Yang H,Delaney WE 4th,et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology,2003,38（1）:96-103.
[24] Salpini R,Svicher V,Cento V,et al. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients,naive to antiviral drugs. Antiviral Research,2011, 92（2）:382-385.
[25] Sayan M,Sentürk O,Akhan S,et al. Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos（t）ide analog resistance mutations in Turkish patients with chronic hepatitis B. Int J Infect Dis,2010,14（3）:136-141.
[26] Amini-Bavil-Olyaee S,Herbers U,Tacke F,et al. Prevalence,viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol,2009,51（4）:647-654.
[27] Rodriguez-Frias F,Jardi R,Esteban R,et al. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther,2008,13（8）:991-999.
[28] JI D,Liu Y,Xu D,et al. Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients. Clin Chim Acta,2011,412（3-4）:305-313.
[29] Schildgen O,Sirma H,Funk A,et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 2006,354（17）:1807-1812.
[30] Schildgen O,Olotu C,Funk A,et al. Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. J clin microbiol,2010,48（2）:631-634.
[31] Geipel A,Glebe D,Will H,et al. Hepatitis B virus rtI233V mutation and resistance to adefovir. N Engl J Med,2014,370（17）:1667-1668.
[32] Curtis M,Zhu Y,Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis, 2007,196（10）:1483-1486.
[33] Ismail AM,Sharma OP,Kumar MS,et al. Impact of rtI233V mutation in hepatitis B virus polymerase protein and adefovir efficacy:Homology modeling and molecular docking studies. Bioinformation,2013,9（3）:121-125.
[34] 邓俊, 于德敏, 张欣欣, 等. 乙型肝炎病毒P基因反转录酶区I233V变异对阿德福韦酯耐药的实验研究. 中华传染病杂志, 2011,29（3）:129-133.
[35] 朱华, 钟彦伟, 徐东平, 等. 乙型肝炎病毒rtN238H变异与阿德福韦酯耐药的相关性研究. 实用肝脏病杂志,2011,14（5）:327-329.
[36] Zhong Y,Lv J,Zhou X,et al. Prevalence,virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B. Antiviral Res,2012,93（1）:185-190.
[37] Yuen MF,Lai CL. Treatment of chronic hepatitis B: evolution over two decades. Gastroenterol Hepatol,2011,26（1）:138-143.
[38] 罗先平,经继生,陈红波,等. 干扰素联合阿德福韦酯治疗慢性乙型肝炎2年随访. 肝脏,2010,15（3）:233-234.

乙型肝炎病毒阿德福韦酯耐药相关变异的研究进展^*

Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[2]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[3]	韩美玲, 陈平. 肝硬化血小板减少患者的抗病毒治疗[J]. 实用肝脏病杂志, 2019, 22(4): 466-469.
[4]	张茜, 胡鹏. 慢性乙型肝炎治愈新药研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 313-317.
[5]	周积云,马勇,丁体龙,涂远航,陈策. 慢性乙型肝炎患者外周血CD8⁺CD28⁺T淋巴细胞百分比的变化及其临床意义探讨[J]. 实用肝脏病杂志, 2019, 22(2): 180-183.
[6]	张欢欢, 杨欢, 沈思兰, 陈佳婕, 宣彬彬. 慢性乙型肝炎患者HBV基因型分布及其耐药基因突变分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 41-44.
[7]	谭静, 叶晓林, 王慧. 妊娠中晚期应用替比夫定阻断HBsAg阳性孕妇HBV母婴传播效果及对婴儿接种乙肝疫苗应答的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 49-52.
[8]	徐静, 陶琳琳, 叶娇娇, 张蕊, 王加加, 袁莉莉, 赵俊奖. 替比夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化患者疗效及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 89-92.
[9]	陈欣, 陈立冬, 李庭红. 替诺福韦酯治疗多重耐药的乙型肝炎肝硬化患者疗效初步研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 681-684.
[10]	张利宁, 刘志刚, 高彩霞, 白桂林, 张晓玲. 授权教育饮食干预在乙型肝炎相关性肾炎患者中的应用研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 799-800.
[11]	明全, 王淑平, 黎春宇, 杨艳艳. 拉米夫定与阿德福韦酯联合治疗失代偿期乙型肝炎肝硬化患者临床疗效研究[J]. 实用肝脏病杂志, 2018, 21(4): 627-628.
[12]	王萍, 周小佳, 刘新华. 视频化健康教育在乙型肝炎病毒相关性肾炎患者中的应用效果研究*[J]. 实用肝脏病杂志, 2018, 21(3): 451-452.
[13]	魏玉, 李华河, 张献波. 恩替卡韦与阿德福韦酯治疗慢性乙型肝炎患者近期疗效和不良反应比较研究[J]. 实用肝脏病杂志, 2018, 21(3): 453-454.
[14]	翁叶蕊, 符爱贞. HBV感染对孕妇产后母乳喂养的影响及护理策略[J]. 实用肝脏病杂志, 2018, 21(3): 457-458.
[15]	邱英锋, 王淑英. 长期应用恩替卡韦治疗拉米夫定耐药的慢性乙型肝炎患者临床疗效及安全性分析*[J]. 实用肝脏病杂志, 2018, 21(2): 196-199.